Core Viewpoint - Guangzheng Eye Hospital (002524.SZ) forecasts a net profit loss of 3 million to 5 million yuan for the year 2025, a significant improvement compared to a loss of 175 million yuan in the same period last year [1]. Financial Performance Summary - The net profit attributable to shareholders is expected to be between -5 million and -3 million yuan, showing a 97.14% improvement compared to the previous year's loss of 174.65 million yuan [2]. - The net profit after deducting non-recurring gains and losses is projected to be between -18 million and -12 million yuan, reflecting a 90.75% increase from last year's loss of 194.52 million yuan [2]. - Basic earnings per share are estimated at -0.0099 yuan, compared to -0.0050 yuan in the previous year [2].

Group 1 - The company, He Eye Hospital, is committed to improving its operations and management while ensuring compliance with regulations [2] - The company aims to explore effective ways and paths for market value management to continuously enhance its intrinsic value [2] - The company seeks to provide long-term stable investment returns for its shareholders [2]

中国上海 , Feb. 02, 2026 (GLOBE NEWSWIRE) -- 总部位于上海的眼科公司，Arctic Vision（“极目生物”），宣布已与杭州的眼科创新医疗器械企业麦得科科技达成战略协议，计划将麦得科科技的眼科器械业务整合进入极目生物体系，推动双方在全球范围内共同构建眼科药械一体化创新平台。 本次战略性合并将把麦得科科技的高端人工晶体（IOL）、有晶体眼人工晶状体（可植入式隐形眼镜 Phakic Lens）与屈光器械平台全面纳入极目生物的全球创新体系。通过结合麦得科科技在先进器械研发、设计与智能制造方面的深厚经验，与极目生物在药物研发与全球化布局方面的优势，双方将共同打造更具前瞻性的综合眼科创新矩阵。 携手加速全球眼科创新进程 该战略整合契合极目生物的长期发展蓝图，也使双方能够在高未满足临床需求的重点领域实现更深层次的协同。 整合完成后，双方预计将形成行业领先的综合管线：既包括极目生物在视网膜、眼表的药物和器械的创新能力，也包括麦得科科技在 IOL 与 屈光晶体研发、设计、制造和工程技术上的核心优势。 按照协议框架，麦得科科技眼科器械业务将纳入极目生物成为统一运营主体的一部分；双方团队将延 ...

科技赋能为成长"睛"彩护航！"AI时代的少年儿童眼健康守护行动"暨"爱阅读 爱眼睛 AI接千万家"系列活动在京启动 未来网北京1月31日电（记者 凌萌）1月30日，"AI时代的少年儿童眼健康守护行动"暨"爱阅读 爱眼睛 AI接千万家"系列活动在京正式启动。本次活动由中国 少年儿童新闻出版总社、中山大学中山眼科中心、中国中医科学院眼科医院联合主办，未来网承办，凝聚政府、学术、医疗、出版及科技领域的多方力量， 旨在深入推进青少年阅读、眼健康和人工智能科技的融合发展，为儿童青少年的全面成长提供更科学、更温暖的守护。 启动仪式在童真洋溢的儿童朗诵表演中拉开帷幕，孩子们用清澈的童音传递着对健康视力与美好未来的向往。 在人工智能技术快速发展、阅读场景日益多元的当下，儿童青少年近视问题日益凸显，成为影响儿童青少年身心健康发展的重大公共卫生问题。中国少年儿 童新闻出版总社党委书记、董事长曾锐在致辞中指出，作为少儿出版领域的"国家队"，中国少年儿童新闻出版总社立足70余年专业积淀，积极从传统内容出 版方向"教育服务者""少年新闻社""品牌运营方"转型，全力构建少儿阅读融合生态。此次联合专业眼科医院发起的眼健康守护行动，将联合多 ...

Core Viewpoint - The Second Global Ophthalmology Conference 2026 will be held on June 11, 2026, in Beijing, focusing on the integration of medicine and engineering, technological innovation, and clinical value in the ophthalmology industry [1]. Event Overview - The conference will cover various fields including ophthalmic imaging, refractive and myopia treatment, innovative therapies, surgical techniques, and preclinical validation [1]. - The event will also open applications for the "2026 Global Ophthalmology Annual Awards" and invite teams to co-author the "Global Ophthalmology Innovation White Paper" [2]. Conference Highlights - The conference will feature the release of the "2026 Global Ophthalmology Innovation White Paper" and the awarding of the "Ophthalmology Innovation Series Awards" to establish industry benchmarks [7]. - There will be premium exhibition spaces for sponsors to engage with high-quality decision-makers, product demonstrations, and collaboration opportunities [7]. - An "Innovation Demo Hour" will allow selected innovative teams to present their projects in 5-10 minute high-density pitches, addressing investment and collaboration needs [14]. Thematic Focus Areas - **Next-Generation Ophthalmic Imaging and AI**: This section will explore the integration of imaging and algorithms, focusing on academic advancements and practical applications [11]. - **Refractive and Myopia**: This segment will address the largest commercial segment in China's ophthalmology industry, discussing refined surgical developments and comprehensive strategies for myopia prevention [13]. - **Surgical Innovations**: This part will showcase the next-generation technologies in ophthalmic surgery, including robotics and real-time imaging [13]. - **Device Development and Preclinical Validation**: This section will present the system of "industrial service chains" to assist R&D and innovation companies in resource matching [13]. Participant Demographics - The conference will attract a diverse audience, including academic teams with recent research outcomes, engineering teams with prototype products, and early-stage innovative companies [16].

Group 1 - The stock of Zhaoke Ophthalmology-B (06622.HK) has increased by over 5%, currently up 5.28% at HKD 3.79 [1] - The trading volume reached HKD 6.119 million [1]

2026年全国征兵工作即将开启，最近，不少怀揣军旅梦的青年来到浙江省眼科医院杭州院区，咨询 视力矫正相关问题。 "近视手术需在参军体检前至少半年完成，以确保留足术前检查、恢复与复查时间。"浙江省眼科医 院杭州院区屈光手术专科门诊副主任医师朱珺提醒，有计划参加今年下半年征兵的青年，最晚要在今年 2月中旬前完成手术。 "根据应征公民体格检查标准，并不是所有视力矫正方式都符合参军要求，比如晶体植入术。"朱珺 介绍，全飞秒、半飞秒、全激光三种角膜激光手术，符合标准即可通过兵检，"由于参军日常训练强度 大、对抗性强，我们更推荐全飞秒激光手术，切口小，术后恢复较快。" 术前需完成三项检查：屈光度数、角膜厚度与形态、眼底视网膜健康状况。已确诊或疑似圆锥角膜 患者，其角膜结构脆弱，近视矫正手术可能会加剧病情发展，须谨慎；术前检查中发现眼底视网膜有问 题（包括但不限于视网膜裂孔、变性、视网膜脱离等），须先规范治疗并复查后再考虑近视手术。 术后科学的恢复与管理也很关键。"术后1—3个月是关键期，比如半飞秒术后不能揉眼。"朱珺强 调，因角膜瓣愈合、神经修复视力稳定等需要3—6个月，因此兵检要求提前半年手术；患者康复后进入 部队，在 ...

Group 1 - The company, Chaoyujian Ophthalmology (02219), announced a share buyback plan [1] - The company will spend HKD 162,000 to repurchase 60,000 shares [1]

Group 1 - The company, Chaoyue Eye Care (02219.HK), announced a share buyback on January 29, spending HKD 162,000 to repurchase 60,000 shares at a price range of HKD 2.68 to HKD 2.71 per share [1]

Core Viewpoint - The successful implantation of the "EVO+ICL(V5)" artificial lens at the Eye Hospital in Yongzhou marks a significant advancement in vision correction technology, particularly benefiting athletes like Gao Xiang who face challenges due to high myopia [1][9]. Group 1: Patient Experience and Needs - Gao Xiang, a key player in the Xiangchao championship team, struggled with severe myopia of approximately 800 degrees, which affected his performance on the field [3]. - The decision to undergo surgery was driven by the need for clear vision during training and competitions, as wearing contact lenses caused discomfort and impacted his performance [3][5]. Group 2: Technological Advancements - The "EVO+ICL(V5)" lens is recognized for its advantages such as non-invasive corneal procedures, strong reversibility, and a wide range of correction, making it a preferred choice for athletes [4]. - The V5 lens features an expanded optical zone of 6.1mm, enhancing night vision and reducing visual disturbances like glare and halos, which is crucial for athletes [4]. Group 3: Surgical Process and Expertise - Prior to the surgery, over 20 detailed eye examinations were conducted to assess Gao Xiang's eye condition, ensuring a personalized surgical plan was developed [5][7]. - Dr. Huang Haitao, with over 30 years of experience and nearly 20,000 surgeries performed, led the operation, emphasizing the importance of safety and tailored solutions for athletes [7]. Group 4: Post-Surgery Outcomes - Post-operative assessments showed Gao Xiang achieving a vision of 1.2 in the right eye and 1.0+ in the left eye, leading to a significant improvement in his visual clarity and overall training focus [7]. - Gao Xiang expressed high satisfaction with the surgery and the professional service provided by the Eye Hospital, highlighting the positive impact on his athletic performance [7]. Group 5: Industry Recognition - During the 14th "Caring for Myopia・Smile Forum," Aier Eye Hospital received dual recognition, with six hospitals becoming part of the "EVO+ ICL(V5) Clinical Research Alliance" and 14 experts recognized as initial clinical application specialists [9]. - The successful surgery of Gao Xiang not only showcases the technology's benefits for athletes but also reinforces Aier Eye Hospital's strength in the field of refractive surgery [9].